Keyphrases
Autoantibodies
100%
Antinuclear Antibodies
100%
Idiopathic Pulmonary Fibrosis
100%
Forced Vital Capacity
88%
Rheumatoid Factor
44%
Progression-free Survival
44%
Antibody-negative
44%
Placebo
33%
Anti-cyclic Citrullinated Peptide Antibody (anti-CCP)
33%
Pirfenidone
33%
Patient Benefit
22%
Connective Tissue Disease
22%
Interstitial Lung Disease
11%
Disease Progression
11%
Autoimmune
11%
Serological Test
11%
Treatment Outcome
11%
Newly Diagnosed
11%
Disease Course
11%
Baseline Characteristics
11%
Trial Registration
11%
Clinical Practice Guidelines
11%
Survival Outcomes
11%
Disease Diagnosis
11%
Centromere
11%
Staining Pattern
11%
Nucleolar
11%
Patient Profile
11%
Unknown Cause
11%
Patient Prognosis
11%
Free Treatment
11%
Fibrosis Diseases
11%
Medicine and Dentistry
Idiopathic Pulmonary Fibrosis
100%
Autoantibodies
100%
Antinuclear Antibody
100%
Post-Hoc Analysis
100%
Forced Vital Capacity
88%
Rheumatoid Factor
44%
Progression Free Survival
44%
Placebo
33%
Pirfenidone
33%
Connective Tissue Disease
22%
Disease
11%
Interstitial Lung Disease
11%
Diagnosis
11%
Disease Exacerbation
11%
Disease Course
11%
Centromere
11%
Peptide
11%
Immunology and Microbiology
Autoantibodies
100%
Antinuclear Antibody
100%
Forced Vital Capacity
88%
Rheumatoid Factor
44%
Progression Free Survival
44%
Connective Tissue
22%
Staining
11%
Centromere
11%